Blood test to help diagnose advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether a blood test (liquid biopsy) can help doctors better understand your lung cancer and plan your treatment. You'll have a blood sample taken alongside standard biopsies to see if the blood test provides useful information about your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced lung cancer suspected on imaging (stage III or IV) that cannot be treated with surgery alone
- Good overall health and ability to care for yourself (ECOG score 0–1)
- Tissue biopsy or cell sample planned or recently done, but lung cancer diagnosis not yet confirmed
- No previous lung cancer diagnosis
- No prior cancer treatment for lung cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
This study tests a simple blood test to find lung cancer early, before symptoms appear. It may help detect cancer sooner, when treatment could be more effective.
This trial uses a simple blood test (liquid biopsy) to find tumor DNA in people suspected of having lung cancer. The goal is to learn if this test can help doctors make better treatment decisions without needing a tissue sample.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
Hear when a new Advanced Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.